Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Cyclophosphamide in Hormone-Refractory Prostate Cancer
NCT01093183Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Mar 2010
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in castration-resistant prostate cancer (CRPC), sponsored by University of Nebraska. Started Mar 2010; status: terminated.
02
Drugs
lenalidomide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01093183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01093183.